You are here
Non Muscle Invasive Bladder Cancer (NMIBC)
This section includes studies on:
- New endovesical therapies for non muscle invasive bladder cancer
- New approaches for high-risk non muscle invasive bladder cancer
- Transurethral resection of bladder tumour (TURBT) techniques and new tools for imaging diagnosis non muscle invasive bladder cancer
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting NMIBC
O'Brien T. Ray E. Chatterton K. Khan M.S. Chandra A. Thomas K.
Category: Bladder03/31/2014
Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer
Barocas DA, Liu A, Burks FN, Suh RS, Schuster TG, Bradford T, Moylan DA, Knapp PM, Murtagh DS, Morris D, Dunn RL, Montie JE, Miller DC.
Category: Bladder03/31/2014
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus calmette-guerin
J Urol. 2013 Oct;190(4):1200-4.
Category: Bladder03/31/2014Comment from Maria Ribal: Treatment for patients with high risk non muscle invasive bladder cancer who experienced recurrence after BCG is a controversial issue. Radical cystectomy must be offered but patients are not always fit enough to be submitted to radical treatment. New agents are being explored as alternative for unfit patients.
Pages
- « first
- ‹ previous
- 1
- 2
- 3
EAU 2017 Scientific Programme and Sessions
View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.